Blood Cancer News and Research

RSS

Skyline Diagnostics launches unique test to detect patients with AML

Each year over eight million people die of cancer worldwide. Patients' chances of survival vary widely: depending on the type of cancer involved, the stage at which it is diagnosed and the speed with which appropriate treatment is launched.

17 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

Bill Gates and Schrödinger co-founder invest in Nimbus to advance large B-cell lymphoma programs

Nimbus Discovery LLC, a biopharmaceutical company using state-of the-art computational technology to discover novel medicines against exciting but difficult-to-drug disease targets, today announced an extension of its seed round with an investment by Bill Gates and Dr. Richard Friesner, the co-founder of Schrödinger and Professor of Chemistry at Columbia University. Atlas Venture, the founding investor, also participated.

11 Mar 2011

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme Therapeutics, Inc. and Roche today announced the first patient received subcutaneous MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze technology.

16 Feb 2011

Scientists reprogram marrow cells from patient with chronic myeloid leukemia

By coaxing healthy and diseased human bone marrow to become embryonic-like stem cells, a team of Wisconsin scientists has laid the groundwork for observing the onset of the blood cancer leukemia in the laboratory dish.

4 Feb 2011

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

For blood cancer patients at high risk of relapse, hematopoietic stem cell transplantation (HSCT), the transplantation of blood-forming stem cells, is one of best options for treatment and a potential cure. Unfortunately, the most common complication of HSCT is graft-versus-host disease (GVHD), a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells recognize the recipient's own cells as foreign and react by attacking the cells in the patient's body.

4 Feb 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

UQAM student identifies gene linked to B-cell acute lymphocytic leukemia

Cyndia Charfi, a Ph. D student in biology at Universit- du Qu-bec - Montr-al (UQAM), supported by her thesis supervisors, Professor -ric Rassart, and Adjunct Professor Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED Research Centre, made a major breakthrough in research on B-cell acute lymphocytic leukemia, a disease that occurs most commonly in children.

19 Jan 2011

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival.

18 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Students donate $6.1 million for cancer research

Students donated a record $6.1 million during Olive Garden's Pasta for Pennies program last year to bring the total amount collected since the program's inception to more than $53 million.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma's ATIR™.

5 Jan 2011

Fundamental similarities in response to wasp infection and blood cancer development

Tiny parasitoid wasps can play an important role in controlling the populations of other insect species by laying their eggs inside the larvae of these species. A newly hatched wasp gradually eats the host alive and takes over its body.

4 Jan 2011

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

23 Dec 2010

Researchers identify new regulator that play a critical role in B cell development

A team at the Institut de recherches cliniques de Montr-al led by Dr. Tarik M-r-y, President and Scientific Director of the institute and Director of the Hematopoiesis and Cancer research unit, will be publishing an important breakthrough in tomorrow's issue of Immunity, a scientific journal from the Cell Press group. The researchers identified a new regulator playing a critical role in the development B cells, which produce antibodies.

23 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010